Quality of life and surgical outcomes in incidental pituitary adenomas undergoing endoscopic endonasal resection
Journal of Neurosurgery · 01.02.2023 · 138 (2) · 567-573
DOI: 10.3171/2022.5.jns2286 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Neurosurgery, erschienen am 01.02.2023. Verfasst von Mendel Castle-Kirszbaum und 4 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Neurosurgery, Monash Health, Melbourne. Hauptthemen laut MEDLINE: Pituitary Neoplasms, Adenoma. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE Incidental, asymptomatic pituitary adenomas require nuanced, shared decision-making, which is limited by a poor understanding of their natural history and effects on quality of life (QOL). A greater understanding of the effects of surgery would inform evidence-based care. METHODS A multicenter review of consecutive pituitary adenomas resected via an endoscopic endonasal approach (EEA) between late 2016 and mid-2021 was performed, with prospective, longitudinal QOL assessment (at 3 and 6 weeks and at 3, 6, and 12 months) postoperatively using the 35-item Anterior Skull Base Questionnaire. RESULTS Of 366 adenomas resected during the study period, 52 (14.2%) were incidentally discovered, of which 51 (98.1%) were macroadenomas. Preoperative QOL in patients with these incidentalomas was better than in those with adenomas presenting with endocrinopathy (p < 0.01), visual failure (p = 0.02), or headache (p = 0.03). Surgery was performed due to visual field deficits (13.5%, n = 7); ophthalmoplegia (1.9%, n = 1); radiological compression or contact of the optic apparatus (63.5%, n = 33); functional status (growth hormone–secreting tumor) (5.8%, n = 3); and clinically significant growth (15.4%, n = 8). Surgical outcomes were excellent, with vision improved in 100% (7/7) and complete resection in 84.6% (44/52). There were 2 (3.8%) cases of new cortisol deficiency, 3 (5.8%) cases of transient postoperative diabetes insipidus, and 4 (7.7%) cases of postoperative hyponatremia. There were no perioperative complications and no cases of postoperative CSF leakage. QOL transiently decreased during the first 3 weeks after surgery, then improved to above baseline levels by 3 months (p = 0.03) and continued to improve throughout the first postoperative year (p = 0.03). All surgical indications demonstrated an overall mean improvement in QOL at 3 months. QOL benefits were not affected by age or tumor size. CONCLUSIONS Resection of pituitary adenomas via the EEA provided a tangible benefit for patients within 3 months. Surgery via the EEA is safe, effective, and beneficial for patients with pituitary incidentalomas meeting accepted criteria for intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 1Department of Neurosurgery, Monash Health, Melbourne.
- 4Department of Surgery, Monash University, Melbourne, Australia.
- 2Department of Neurosurgery, St. Vincent's Health, Melbourne.
- 3Department of Neurosurgery, Royal Melbourne Hospital, Melbourne; and.
Zitieren
APA
Castle-Kirszbaum, M., Wang, Y. Y., King, J., Kam, J., & Goldschlager, T. (2023). Quality of life and surgical outcomes in incidental pituitary adenomas undergoing endoscopic endonasal resection. Journal of Neurosurgery, 138(2), 567-573. https://doi.org/10.3171/2022.5.jns2286
Vancouver
Castle-Kirszbaum M, Wang YY, King J, Kam J, Goldschlager T. Quality of life and surgical outcomes in incidental pituitary adenomas undergoing endoscopic endonasal resection. Journal of Neurosurgery. 2023;138(2):567-573. doi:10.3171/2022.5.jns2286
BibTeX
@article{CastleKirszbaum2023,
author = {Castle-Kirszbaum, Mendel and Wang, Yi Yuen and King, James and Kam, Jeremy and Goldschlager, Tony},
title = {Quality of life and surgical outcomes in incidental pituitary adenomas undergoing endoscopic endonasal resection},
journal = {Journal of Neurosurgery},
year = {2023},
volume = {138},
number = {2},
pages = {567--573},
doi = {10.3171/2022.5.jns2286}
}
EUVIMED